Arbutus Biopharma Corp (ABUS) stock forecast · P/E 5.4, rev $180.1M
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
This ABUS forecast page states what the cached financials imply — not a price target and not a guarantee. Arbutus Biopharma Corp outlooks on Lician start from reported revenue and the latest filing, then you decide.
Latest reported ABUS revenue for 2026-06-30 was $180.1M. Net income was $164.6M. Revenue was up 0.6% from 2026-03-31 to 2026-06-30. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
The near-term path: Revenue was up 0.6% from 2026-03-31 to 2026-06-30. A forecast that ignores that change is just a story.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. Stretching today's multiple into 2026 without a filing reason is how thin forecast pages get ignored.
When the next ABUS 10-Q or 8-K lands, this outlook should move. Until then the SEC page is the source.
Not a prediction market. For the live quote and the full model, use the ABUS stock page.
Not investment advice.